54 results on '"Rivella, Stefano"'
Search Results
2. Combination of a TGF‐β ligand trap (RAP‐GRL) and TMPRSS6‐ASO is superior for correcting β‐thalassemia.
- Author
-
Guerra, Amaliris, Hamilton, Nolan, Rivera, Ariel, Demsko, Perry, Guo, Shuling, and Rivella, Stefano
- Published
- 2024
- Full Text
- View/download PDF
3. Normal and dysregulated crosstalk between iron metabolism and erythropoiesis.
- Author
-
Ginzburg, Yelena, Xuili An, Rivella, Stefano, and Goldfarb, Adam
- Published
- 2023
- Full Text
- View/download PDF
4. In vivo hematopoietic stem cell modification by mRNA delivery.
- Author
-
Breda, Laura, Papp, Tyler E., Triebwasser, Michael P., Yadegari, Amir, Fedorky, Megan T., Naoto Tanaka, Abdulmalik, Osheiza, Pavani, Giulia, Yongping Wang, Grupp, Stephan A., Chou, Stella T., Houping Ni, Mui, Barbara L., Tam, Ying K., Weissman, Drew, Rivella, Stefano, and Parhiz, Hamideh
- Published
- 2023
- Full Text
- View/download PDF
5. TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis.
- Author
-
Ganz, Tomas, Nemeth, Elizabeta, Rivella, Stefano, Goldberg, Paul, Dibble, Andrew R., McCaleb, Michael L., Guo, Shuling, Monia, Brett P., and Barrett, Terrance D.
- Abstract
TMPRSS6 is a serine protease highly expressed in the liver. Its role in iron regulation was first reported in 2008 when mutations in TMPRSS6 were shown to be the cause of iron-refractory iron deficiency anemia (IRIDA) in humans and in mouse models. TMPRSS6 functions as a negative regulator of the expression of the systemic iron-regulatory hormone hepcidin. Over the last decade and a half, growing understanding of TMPRSS6 biology and mechanism of action has enabled development of new therapeutic approaches for patients with diseases of erythropoiesis and iron homeostasis. ClinicalTrials.gov identifier NCT03165864. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion‐independent a murine model of transfusion‐dependent β‐thalassemia.
- Author
-
Di Modica, Simona Maria, Tanzi, Emanuele, Olivari, Violante, Lidonnici, Maria Rosa, Pettinato, Mariateresa, Pagani, Alessia, Tiboni, Francesca, Furiosi, Valeria, Silvestri, Laura, Ferrari, Giuliana, Rivella, Stefano, and Nai, Antonella
- Published
- 2022
- Full Text
- View/download PDF
7. Tmprss6-ASO as a tool for the treatment of Polycythemia Vera mice.
- Author
-
Casu, Carla, Liu, Alison, De Rosa, Gianluca, Low, Audrey, Suzuki, Aae, Sinha, Sayantani, Ginzburg, Yelena Z., Abrams, Charles, Aghajan, Mariam, Guo, Shuling, and Rivella, Stefano
- Subjects
POLYCYTHEMIA vera ,MYELOPROLIFERATIVE neoplasms ,MICE ,THROMBOEMBOLISM ,HEMATOCRIT - Abstract
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm resulting from an acquired driver mutation in the JAK2 gene of hematopoietic stem and progenitor cells resulting in the overproduction of mature erythrocytes and abnormally high hematocrit, in turn leading to thromboembolic complications. Therapeutic phlebotomy is the most common treatment to reduce the hematocrit levels and consequently decrease thromboembolic risk. Here we demonstrate that, by using the iron restrictive properties of the antisense oligonucleotides against Tmprss6 mRNA, we can increase hepcidin to achieve effects equivalent to therapeutic phlebotomy. We provide evidence that this less invasive approach could represent an additional therapeutic tool for the treatment of PV patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia.
- Author
-
Lam, L. K. Metthew, Murphy, Sophia, Kokkinaki, Dimitra, Venosa, Alessandro, Sherrill-Mix, Scott, Casu, Carla, Rivella, Stefano, Weiner, Aaron, Park, Jeongho, Shin, Sunny, Vaughan, Andrew E., Hahn, Beatrice H., Odom John, Audrey R., Meyer, Nuala J., Hunter, Christopher A., Worthen, G. Scott, and Mangalmurti, Nilam S.
- Subjects
ERYTHROCYTES ,MITOCHONDRIAL DNA ,COVID-19 ,BACTERIAL DNA ,DNA ,NUCLEIC acids - Abstract
keyimage.jpg DNA sensing by RBCs: Red blood cells (RBCs) have historically been considered immunologically inert. In this study, however, Lam et al. demonstrated that RBCs promote inflammation through expression of Toll-like receptor 9 (TLR9) on the cell surface. The authors observed that RBC-expressed TLR9 bound DNA from bacteria, plasmodia, and mitochondria in vitro, and RBC-bound DNA was enriched in humans and mice during sepsis. This drove erythrophagocytosis by splenic macrophages, resulting in acute anemia. Last, the authors show that RBC-bound mitochondrial DNA was enriched in the peripheral blood of patients with viral pneumonia or sepsis secondary to coronavirus disease 2019 (COVID-19). Together, these findings show that RBCs are essential components of inflammatory responses. Red blood cells (RBCs) are essential for aerobic respiration through delivery of oxygen to distant tissues. However, RBCs are currently considered immunologically inert, and few, if any, secondary functions of RBCs have been identified. Here, we showed that RBCs serve as critical immune sensors through surface expression of the nucleic acid–sensing Toll-like receptor 9 (TLR9). Mammalian RBCs expressed TLR9 on their surface and bound CpG-containing DNA derived from bacteria, plasmodia, and mitochondria. RBC-bound mitochondrial DNA was increased during human and murine sepsis and pneumonia. In vivo, CpG-carrying RBCs drove accelerated erythrophagocytosis and innate immune activation characterized by increased interferon signaling. Erythroid-specific deletion of TLR9 abrogated erythrophagocytosis and decreased local and systemic cytokine production during CpG-induced inflammation and polymicrobial sepsis. Thus, detection and capture of nucleic acid by TLR9-expressing RBCs regulated red cell clearance and inflammatory cytokine production, demonstrating that RBCs function as immune sentinels during pathologic states. Consistent with these findings, RBC-bound mitochondrial DNA was elevated in individuals with viral pneumonia and sepsis secondary to coronavirus disease 2019 (COVID-19) and associated with anemia and severity of disease. These findings uncover a previously unappreciated role of RBCs as critical players in inflammation distinct from their function in gas transport. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. The Role of Iron in Benign and Malignant Hematopoiesis.
- Author
-
Sinha, Sayantani, Pereira-Reis, Joana, Guerra, Amaliris, Rivella, Stefano, and Duarte, Delfim
- Published
- 2021
- Full Text
- View/download PDF
10. The hepcidin regulator erythroferrone is a new member of the erythropoiesis-iron-bone circuitry.
- Author
-
Castro-Mollo, Melanie, Gera, Sakshi, Ruiz-Martinez, Marc, Feola, Maria, Gumerova, Anisa, Planoutene, Marina, Clementelli, Cara, Sangkhae, Veena, Casu, Carla, Se-Min Kim, Ostland, Vaughn, Huiling Han, Nemeth, Elizabeta, Fleming, Robert, Rivella, Stefano, Lizneva, Daria, Yuen, Tony, Zaidi, Mone, and Ginzburg, Yelena
- Published
- 2021
- Full Text
- View/download PDF
11. Pleckstrin-2 is essential for erythropoiesis in β-thalassemic mice, reducing apoptosis and enhancing enucleation.
- Author
-
Feola, Maria, Zamperone, Andrea, Moskop, Daniel, Chen, Huiyong, Casu, Carla, Lama, Dechen, Di Martino, Julie, Djedaini, Mansour, Papa, Luena, Martinez, Marc Ruiz, Choesang, Tenzin, Bravo-Cordero, Jose Javier, MacKay, Matthew, Zumbo, Paul, Brinkman, Nathan, Abrams, Charles S., Rivella, Stefano, Hattangadi, Shilpa, Mason, Christopher E., and Hoffman, Ronald
- Subjects
ERYTHROPOIESIS ,CELL differentiation ,CELL enucleation ,TRANSFERRIN ,APOPTOSIS - Abstract
Erythropoiesis involves complex interrelated molecular signals influencing cell survival, differentiation, and enucleation. Diseases associated with ineffective erythropoiesis, such as β-thalassemias, exhibit erythroid expansion and defective enucleation. Clear mechanistic determinants of what make erythropoiesis effective are lacking. We previously demonstrated that exogenous transferrin ameliorates ineffective erythropoiesis in β-thalassemic mice. In the current work, we utilize transferrin treatment to elucidate a molecular signature of ineffective erythropoiesis in β-thalassemia. We hypothesize that compensatory mechanisms are required in β-thalassemic erythropoiesis to prevent apoptosis and enhance enucleation. We identify pleckstrin-2—a STAT5-dependent lipid binding protein downstream of erythropoietin—as an important regulatory node. We demonstrate that partial loss of pleckstrin-2 leads to worsening ineffective erythropoiesis and pleckstrin-2 knockout leads to embryonic lethality in β-thalassemic mice. In addition, the membrane-associated active form of pleckstrin-2 occurs at an earlier stage during β-thalassemic erythropoiesis. Furthermore, membrane-associated activated pleckstrin-2 decreases cofilin mitochondrial localization in β-thalassemic erythroblasts and pleckstrin-2 knockdown in vitro induces cofilin-mediated apoptosis in β-thalassemic erythroblasts. Lastly, pleckstrin-2 enhances enucleation by interacting with and activating RacGTPases in β-thalassemic erythroblasts. This data elucidates the important compensatory role of pleckstrin-2 in β-thalassemia and provides support for the development of targeted therapeutics in diseases of ineffective erythropoiesis. Maria Feola et al., elucidate the compensatory role of pleckstrin-2 in ineffective erythropoiesis in β-thalassemic mice by reducing cofilin-mediated apoptosis and enhancing enucleation by activating RacGTPases. These findings could support future therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Mitochondria Biogenesis Modulates Iron–Sulfur Cluster Synthesis to Increase Cellular Iron Uptake.
- Author
-
La, Ping, Oved, Joseph H., Ghiaccio, Valentina, and Rivella, Stefano
- Subjects
MITOCHONDRIA formation ,TRANSFERRIN ,TRANSFERRIN receptors ,NUCLEAR receptors (Biochemistry) - Abstract
Iron–sulfur (Fe-S) clusters are required for mitochondrial function. Fe-S cluster synthesis occurs in the mitochondria and iron uptake is required for mitochondrial biogenesis. However, Fe-S clusters inhibit the expression of the iron importer transferrin receptor 1 (TfR1), whereas lack of the Fe-S cluster stimulates TfR1 expression. Yet, it is unclear whether Fe-S cluster synthesis increases with mitochondria biogenesis and, in turn, whether this negatively modulates TfR1 expression. We manipulated peroxisome proliferator-activated receptor-gamma coactivator-1α expression to control mitochondrial biogenesis in a variety of cell types, including erythroid cells. We demonstrated that Fe-S cluster synthesis increases with mitochondria biogenesis but does not interfere with increasing TfR1 expression. In fact, TfR1 expression is stimulated through alternative means to meet iron requirement for mitochondria biogenesis. Furthermore, under enhanced mitochondria biogenesis, increased Fe-S cluster synthesis inhibits the function of iron-regulating protein (IRP)1 and hence stimulates the expression of 5′-aminolevulinate synthase 2 (ALAS2), a target of IRP1 and rate-limiting enzyme in erythroid heme biogenesis. Increased ALAS2 expression leads to enhanced heme production, hemoglobinization, and erythropoiesis. Therefore, our study also provides a mechanism to link mitochondrial biogenesis with erythropoiesis and has a potential therapeutic value in the treatment of blood disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Development and characterization of cellular biosensors for HTS of erythroid differentiation inducers targeting the transcriptional activity of γ-globin and β-globin gene promoters.
- Author
-
Breveglieri, Giulia, Salvatori, Francesca, Finotti, Alessia, Cosenza, Lucia Carmela, Zuccato, Cristina, Bianchi, Nicoletta, Breda, Laura, Rivella, Stefano, Bresciani, Alberto, Bisbocci, Monica, Borgatti, Monica, and Gambari, Roberto
- Subjects
FETAL hemoglobin ,SICKLE cell anemia ,BIOSENSORS ,GENE expression ,PROMOTERS (Genetics) ,GENES - Abstract
There is a general agreement that pharmacologically mediated stimulation of human γ-globin gene expression and increase of production of fetal hemoglobin (HbF) is a potential therapeutic approach in the experimental therapy of β-thalassemia and sickle cell anemia. Here, we report the development and characterization of cellular biosensors carrying enhanced green fluorescence protein (EGFP) and red fluorescence protein (RFP) genes under the control of the human γ-globin and β-globin gene promoters, respectively; these dual-reporter cell lines are suitable to identify the induction ability of screened compounds on the transcription in erythroid cells of γ-globin and β-globin genes by FACS with efficiency and reproducibility. Our experimental system allows to identify (a) HbF inducers stimulating to different extent the activity of the γ-globin gene promoter and (b) molecules that stimulate also the activity of the β-globin gene promoter. A good correlation does exist between the results obtained by using the EGFP/RFP clones and experiments performed on erythroid precursor cells from β-thalassemic patients, confirming that this experimental system can be employed for high-throughput screening (HTS) analysis. Finally, we have demonstrated that this dual-reporter cell line can be used for HTS in 384-well plate, in order to identify novel HbF inducers for the therapy of β-thalassemia and sickle cell anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Gene therapy of hemoglobinopathies: progress and future challenges.
- Author
-
Ikawa, Yasuhiro, Miccio, Annarita, Magrin, Elisa, Kwiatkowski, Janet L, Rivella, Stefano, and Cavazzana, Marina
- Published
- 2019
- Full Text
- View/download PDF
15. Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.
- Author
-
Ghiaccio, Valentina, Chappell, Maxwell, Rivella, Stefano, and Breda, Laura
- Subjects
GENE therapy ,FETAL hemoglobin ,GENOME editing ,HEMATOPOIETIC stem cells ,BONE marrow transplantation ,GENETIC transformation - Abstract
Inherited monogenic disorders such as beta-hemoglobinopathies (BH) are fitting candidates for treatment via gene therapy by gene transfer or gene editing. The reported safety and efficacy of lentiviral vectors in preclinical studies have led to the development of several clinical trials for the addition of a functional beta-globin gene. Across trials, dozens of transfusion-dependent patients with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) have been treated via gene therapy and have achieved reduced transfusion requirements. While overall results are encouraging, the outcomes appear to be strongly influenced by the level of lentiviral integration in transduced cells after engraftment, as well as the underlying genotype resulting in thalassemia. In addition, the method of procurement of hematopoietic stem cells can affect their quality and thus the outcome of gene therapy both in SCD and TDT. This suggests that new studies aimed at maximizing the number of corrected cells with long-term self-renewal potential are crucial to ensure successful treatment for every patient. Recent advancements in gene transfer and bone marrow transplantation have improved the success of this approach, and the results obtained by using these strategies demonstrated significant improvement of gene transfer outcome in patients. The advent of new gene-editing technologies has suggested additional therapeutic options. These are primarily focused on correcting the defective beta-globin gene or editing the expression of genes or genomic segments that regulate fetal hemoglobin synthesis. In this review, we aim to establish the potential benefits of gene therapy for BH, to summarize the status of the ongoing trials, and to discuss the possible improvement or direction for future treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Management of non‐transfusion‐dependent β‐thalassemia (NTDT): The next 5 years.
- Author
-
Musallam, Khaled M., Rivella, Stefano, and Taher, Ali T.
- Published
- 2021
- Full Text
- View/download PDF
17. Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later.
- Author
-
Musallam, Khaled M., Cappellini, Maria D., Viprakasit, Vip, Kattamis, Antonis, Rivella, Stefano, and Taher, Ali T.
- Published
- 2021
- Full Text
- View/download PDF
18. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia.
- Author
-
Agoro, Rafiou, Montagna, Anna, Goetz, Regina, Aligbe, Onyedikachi, Singh, Gurinder, Coe, Lindsay M., Mohammadi, Moosa, Rivella, Stefano, and Sitara, Despina
- Published
- 2018
- Full Text
- View/download PDF
19. Red Blood Cells Homeostatically Bind Mitochondrial DNA through TLR9 to Maintain Quiescence and to Prevent Lung Injury.
- Author
-
Hotz, Meghan J., Qing, Danielle, Shashaty, Michael G. S., Zhang, Peggy, Faust, Hilary, Sondheimer, Neal, Rivella, Stefano, Worthen, G. Scott, and Mangalmurti, Nilam S.
- Abstract
Rationale: Potentially hazardous CpG-containing cell-free mitochondrial DNA (cf-mtDNA) is routinely released into the circulation and is associated with morbidity and mortality in critically ill patients. How the body avoids inappropriate innate immune activation by cf-mtDNA remains unknown. Because red blood cells (RBCs) modulate innate immune responses by scavenging chemokines, we hypothesized that RBCs may attenuate CpG-induced lung inflammation through direct scavenging of CpG-containing DNA.Objectives: To determine the mechanisms of CpG-DNA binding to RBCs and the effects of RBC-mediated DNA scavenging on lung inflammation.Methods: mtDNA on murine RBCs was measured under basal conditions and after systemic inflammation. mtDNA content on human RBCs from healthy control subjects and trauma patients was measured. Toll-like receptor 9 (TLR9) expression on RBCs and TLR9-dependent binding of CpG-DNA to RBCs were determined. A murine model of RBC transfusion after CpG-DNA-induced lung injury was used to investigate the role of RBC-mediated DNA scavenging in mitigating lung injury in vivo.Measurements and Main Results: Under basal conditions, RBCs bind CpG-DNA. The plasma-to-RBC mtDNA ratio is low in naive mice and in healthy volunteers but increases after systemic inflammation, demonstrating that the majority of cf-mtDNA is RBC-bound under homeostatic conditions and that the unbound fraction increases during inflammation. RBCs express TLR9 and bind CpG-DNA through TLR9. Loss of TLR9-dependent RBC-mediated CpG-DNA scavenging increased lung injury in vivo.Conclusions: RBCs homeostatically bind mtDNA, and RBC-mediated DNA scavenging is essential in mitigating lung injury after CpG-DNA. Our data suggest a role for RBCs in regulating lung inflammation during disease states where cf-mtDNA is elevated, such as sepsis and trauma. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
20. Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease.
- Author
-
Akchurin, Oleh, Sureshbabu, Angara, Doty, Steve B., Yuan-Shan Zhu, Patino, Edwin, Cunningham-Rundles, Susanna, Choi, Mary E., Boskey, Adele, and Rivella, Stefano
- Subjects
PEDIATRIC nephrology ,GROWTH of children ,DWARFISM ,DISEASE risk factors - Abstract
Growth delay is common in children with chronic kidney disease (CKD), often associated with poor quality of life. The role of anemia in uremic growth delay is poorly understood. Here we describe an induction of uremic growth retardation by a 0.2% adenine diet in wild-type (WT) and hepcidin gene (Hamp) knockout (KO) mice, compared with their respective littermates fed a regular diet. Experiments were started at weaning (3 wk). After 8 wk, blood was collected and mice were euthanized. Adeninefed WT mice developed CKD (blood urea nitrogen 82.8 ± 11.6 mg/dl and creatinine 0.57 ± 0.07 mg/dl) and were 2.1 cm shorter compared with WT controls. WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-α. WT adenine-fed mice had advanced mineral bone disease (serum phosphorus 16.9 ± 3.1 mg/dl and FGF23 204.0 ± 115.0 ng/ml) with loss of cortical and trabecular bone volume seen on microcomputed tomography. Hamp disruption rescued the anemia phenotype resulting in improved growth rate in mice with CKD, thus providing direct experimental evidence of the relationship between Hamp pathway and growth impairment in CKD. Hamp disruption ameliorated CKD-induced growth hormone-insulin-like growth factor 1 axis derangements and growth plate alterations. Disruption of Hamp did not mitigate the development of uremia, inflammation, and mineral and bone disease in this model. Taken together, these results indicate that an adenine diet can be successfully used to study growth in mice with CKD. Hepcidin appears to be related to pathways of growth retardation in CKD suggesting that investigation of hepcidin-lowering therapies in juvenile CKD is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. A validated cellular biobank for β-thalassemia.
- Author
-
Cosenza, Lucia Carmela, Breda, Laura, Breveglieri, Giulia, Zuccato, Cristina, Finotti, Alessia, Lampronti, Ilaria, Borgatti, Monica, Chiavilli, Francesco, Gamberini, Maria Rita, Satta, Stefania, Manunza, Laura, De Martis, Franca Rosa, Moi, Paolo, Rivella, Stefano, Gambari, Roberto, and Bianchi, Nicoletta
- Subjects
THALASSEMIA ,GENE therapy ,PHLEBOTOMISTS ,REPRODUCIBLE research ,ERYTHROCYTES ,MEDICAL research - Abstract
Background: Cellular biobanking is a key resource for collaborative networks planning to use same cells in studies aimed at solving a variety of biological and biomedical issues. This approach is of great importance in studies on β-thalassemia, since the recruitment of patients and collection of specimens can represent a crucial and often limiting factor in the experimental planning.Methods: Erythroid precursor cells were obtained from 72 patients, mostly β-thalassemic, expanded and cryopreserved. Expression of globin genes was analyzed by real time RT-qPCR. Hemoglobin production was studied by HPLC.Results: In this paper we describe the production and validation of a Thal-Biobank constituted by expanded erythroid precursor cells from β-thalassemia patients. The biobanked samples were validated for maintenance of their phenotype after (a) cell isolation from same patients during independent phlebotomies, (b) freezing step in different biobanked cryovials, (c) thawing step and analysis at different time points. Reproducibility was confirmed by shipping the frozen biobanked cells to different laboratories, where the cells were thawed, cultured and analyzed using the same standardized procedures. The biobanked cells were stratified on the basis of their baseline level of fetal hemoglobin production and exposed to fetal hemoglobin inducers.Conclusion: The use of biobanked cells allows stratification of the patients with respect to fetal hemoglobin production and can be used for determining the response to the fetal hemoglobin inducer hydroxyurea and to gene therapy protocols with reproducible results. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
22. New strategies to target iron metabolism for the treatment of beta thalassemia.
- Author
-
Oikonomidou, Paraskevi Rea, Casu, Carla, and Rivella, Stefano
- Subjects
BETA-Thalassemia ,IRON metabolism ,OLIGONUCLEOTIDES ,RED blood cell transfusion ,ANIMAL models in research ,MORTALITY ,THERAPEUTICS - Abstract
Iron is one of the most abundant elements in the Earth and a fundamental component of enzymes and other proteins that participate in a wide range of biological processes. As the human body has no mechanisms to eliminate the excess of iron, its metabolism needs to be tightly controlled in order to avoid all the sequelae associated with high iron levels. Iron overload is the main cause of morbidity and mortality in beta thalassemia. The master regulator of iron homeostasis, hepcidin, is chronically repressed in this disorder, leading to increased intestinal iron absorption and consequent iron overload. Many groups have focused on obtaining a better understanding of the pathways involved in iron regulation. New molecules have recently been synthesized and used in animal models of dysregulated iron metabolism, demonstrating their ability to target and reduce iron load. Antisense oligonucleotides, as well as lipid nanoparticle-formulated small interfering RNAs and minihepcidins peptides, are novel agents that have already proved to be efficient in modulating iron metabolism in mouse models and are therefore promising candidates for the treatment of patients affected by iron disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Altered erythropoiesis and iron metabolism in carriers of thalassemia.
- Author
-
Guimarães, Jacqueline S., Cominal, Juçara G., Silva‐Pinto, Ana Cristina, Olbina, Gordana, Ginzburg, Yelena Z., Nandi, Vijay, Westerman, Mark, Rivella, Stefano, and Souza, Ana Maria
- Subjects
THALASSEMIA ,HEMOGLOBINOPATHY ,SYNDROMES ,HEPCIDIN ,ERYTHROPOIETIN ,IRON metabolism ,ERYTHROPOIESIS - Abstract
The thalassemia syndromes (α- and β-thalassemia) are the most common and frequent disorders associated with ineffective erythropoiesis. Imbalance of α- or β-globin chain production results in impaired red blood cell synthesis, anemia, and more erythroid progenitors in the blood stream. While patients affected by these disorders show definitive altered parameters related to erythropoiesis, the relationship between the degree of anemia, altered erythropoiesis, and dysfunctional iron metabolism has not been investigated in both α-thalassemia carriers ( ATC) and β-thalassemia carriers ( BTC). Here, we demonstrate that ATC have a significantly reduced hepcidin and increased soluble transferrin receptor levels but relatively normal hematological findings. In contrast, BTC have several hematological parameters significantly different from controls, including increased soluble transferrin receptor and erythropoietin levels. These changes in both groups suggest an altered balance between erythropoiesis and iron metabolism. The index s Tf R/log ferritin and (hepcidin/ferritin)/s Tf R are, respectively, increased and reduced relative to controls, proportional to the severity of each thalassemia group. In conclusion, we showed in this study, for the first time in the literature, that thalassemia carriers have altered iron metabolism and erythropoiesis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Generation and Characterization of a Transgenic Mouse Carrying a Functional Human β -Globin Gene with the IVSI-6 Thalassemia Mutation.
- Author
-
Breveglieri, Giulia, Mancini, Irene, Bianchi, Nicoletta, Lampronti, Ilaria, Salvatori, Francesca, Fabbri, Enrica, Zuccato, Cristina, Cosenza, Lucia C., Montagner, Giulia, Borgatti, Monica, Altruda, Fiorella, Fagoonee, Sharmila, Carandina, Gianni, Rubini, Michele, Aiello, Vincenzo, Breda, Laura, Rivella, Stefano, Gambari, Roberto, and Finotti, Alessia
- Subjects
GENETICS of thalassemia ,ANIMAL experimentation ,BIOLOGICAL models ,ELECTROPHORESIS ,GENES ,RESEARCH methodology ,MICE ,GENETIC mutation ,POLYMERASE chain reaction ,RESEARCH funding ,TISSUE culture ,WESTERN immunoblotting ,FLUORESCENCE in situ hybridization - Abstract
Mouse models that carry mutations causing thalassemia represent a suitable tool to test in vivo new mutation-specific therapeutic approaches. Transgenic mice carrying the β-globin IVSI-6 mutation (the most frequent in Middle-Eastern regions and recurrent in Italy and Greece) are, at present, not available. We report the production and characterization of a transgenic mouse line (TG-β-IVSI-6) carrying the IVSI-6 thalassemia point mutation within the human β-globin gene. In the TG-β-IVSI-6 mouse (a) the transgenic integration region is located in mouse chromosome 7; (b) the expression of the transgene is tissue specific; (c) as expected, normally spliced human β-globin mRNA is produced, giving rise to β-globin production and formation of a human-mouse tetrameric chimeric hemoglobin αmu-globin
2 /βhu-globin2 and, more importantly, (d) the aberrant β-globin-IVSI-6 RNAs are present in blood cells. The TG-β-IVSI-6 mouse reproduces the molecular features of IVSI-6 β-thalassemia and might be used as an in vivo model to characterize the effects of antisense oligodeoxynucleotides targeting the cryptic sites responsible for the generation of aberrantly spliced β-globin RNA sequences, caused by the IVSI-6 mutation. These experiments are expected to be crucial for the development of a personalized therapy for β-thalassemia. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
25. Recent trends in the gene therapy of β-thalassemia.
- Author
-
Finotti, Alessia, Bianchi, Nicoletta, Zuccato, Cristina, Gambari, Roberto, Breda, Laura, Rivella, Stefano, Lederer, Carsten W., and Kleanthous, Marina
- Subjects
THALASSEMIA ,GLOBIN genes ,FETAL hemoglobin ,TRANSCRIPTION factors ,INDUCED pluripotent stem cells ,GENOME editing ,GENE therapy - Abstract
The β-thalassemias are a group of hereditary hematological diseases caused by over 300 mutations of the adult β-globin gene. Together with sickle cell anemia, thalassemia syndromes are among the most impactful diseases in developing countries, in which the lack of genetic counseling and prenatal diagnosis have contributed to the maintenance of a very high frequency of these genetic diseases in the population. Gene therapy for β-thalassemia has recently seen steadily accelerating progress and has reached a crossroads in its development. Presently, data from past and ongoing clinical trials guide the design of further clinical and preclinical studies based on gene augmentation, while fundamental insights into globin switching and new technology developments have inspired the investigation of novel gene-therapy approaches. Moreover, human erythropoietic stem cells from β-thalassemia patients have been the cellular targets of choice to date whereas future gene-therapy studies might increasingly draw on induced pluripotent stem cells. Herein, we summarize the most significant developments in β-thalassemia gene therapy over the last decade, with a strong emphasis on the most recent findings, for β-thalassemia model systems; for β-, γ-, and anti-sickling β-globin gene addition and combinatorial approaches including the latest results of clinical trials; and for novel approaches, such as transgene-mediated activation of γ-globin and genome editing using designer nucleases. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
26. Disorders of Red Cell Production and the Iron-Loading Anemias.
- Author
-
Rivella, Stefano
- Published
- 2012
- Full Text
- View/download PDF
27. FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis.
- Author
-
Zhang, Xin, Campreciós, Genís, Rimmelé, Pauline, Liang, Raymond, Yalcin, Safak, Mungamuri, Sathish Kumar, Barminko, Jeffrey, D'Escamard, Valentina, Baron, Margaret H., Brugnara, Carlo, Papatsenko, Dmitri, Rivella, Stefano, and Ghaffari, Saghi
- Published
- 2014
- Full Text
- View/download PDF
28. Identification of erythroferrone as an erythroid regulator of iron metabolism.
- Author
-
Kautz, Léon, Jung, Grace, Valore, Erika V, Rivella, Stefano, Nemeth, Elizabeta, and Ganz, Tomas
- Subjects
HEMORRHAGE ,IRON in the body ,ERYTHROPOIESIS ,HEPCIDIN ,BETA-Thalassemia - Abstract
Recovery from blood loss requires a greatly enhanced supply of iron to support expanded erythropoiesis. After hemorrhage, suppression of the iron-regulatory hormone hepcidin allows increased iron absorption and mobilization from stores. We identified a new hormone, erythroferrone (ERFE), that mediates hepcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress hepcidin rapidly after hemorrhage and exhibit a delay in recovery from blood loss. ERFE expression is greatly increased in Hbb
th3/+ mice with thalassemia intermedia, where it contributes to the suppression of hepcidin and the systemic iron overload characteristic of this disease. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
29. Iron and Reactive Oxygen Species: Friends or Foes of Cancer Cells?
- Author
-
Bystrom, Laura M., Guzman, Monica L., and Rivella, Stefano
- Published
- 2014
- Full Text
- View/download PDF
30. Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia.
- Author
-
Ramos, Pedro, Casu, Carla, Gardenghi, Sara, Breda, Laura, Crielaard, Bart J, Guy, Ella, Marongiu, Maria Franca, Gupta, Ritama, Levine, Ross L, Abdel-Wahab, Omar, Ebert, Benjamin L, Van Rooijen, Nico, Ghaffari, Saghi, Grady, Robert W, Giardina, Patricia J, and Rivella, Stefano
- Subjects
ERYTHROPOIESIS ,MACROPHAGES ,ANEMIA ,POLYCYTHEMIA ,THALASSEMIA - Abstract
Regulation of erythropoiesis is achieved by the integration of distinct signals. Among them, macrophages are emerging as erythropoietin-complementary regulators of erythroid development, particularly under stress conditions. We investigated the contribution of macrophages to physiological and pathological conditions of enhanced erythropoiesis. We used mouse models of induced anemia, polycythemia vera and β-thalassemia in which macrophages were chemically depleted. Our data indicate that macrophages contribute decisively to recovery from induced anemia, as well as the pathological progression of polycythemia vera and β-thalassemia, by modulating erythroid proliferation and differentiation. We validated these observations in primary human cultures, showing a direct impact of macrophages on the proliferation and enucleation of erythroblasts from healthy individuals and patients with polycythemia vera or β-thalassemia. The contribution of macrophages to stress and pathological erythropoiesis, which we have termed stress erythropoiesis macrophage-supporting activity, may have therapeutic implications. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
31. A combined approach for β-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction.
- Author
-
Zuccato, Cristina, Breda, Laura, Salvatori, Francesca, Breveglieri, Giulia, Gardenghi, Sara, Bianchi, Nicoletta, Brognara, Eleonora, Lampronti, Ilaria, Borgatti, Monica, Rivella, Stefano, and Gambari, Roberto
- Subjects
THALASSEMIA ,GENE therapy ,HEMOGLOBINS ,GLOBIN ,GENETIC transformation ,CELL lines ,MESSENGER RNA - Abstract
Gene therapy might fall short in achieving a complete reversion of the β-thalassemic phenotype due to current limitations in vector design and myeloablative regimen. Following gene transfer, all or a large proportion of erythroid cells might express suboptimal levels of β-globin, impairing the therapeutic potential of the treatment. Our aim was to evaluate whether, in absence of complete reversion of the β-globin phenotype upon gene transfer, it is possible to use fetal hemoglobin induction to eliminate the residual α-globin aggregates and achieve normal levels of hemoglobin. Transgenic K562 cell lines and erythroid precursor cells from β39-thalassemia patients were employed. Gene therapy was performed with the lentiviral vector T9W. Induction of fetal hemoglobin was obtained using mithramycin. Levels of mRNA and hemoglobins were determined by qRT-PCR and HPLC. First, we analyzed the effect of mithramycin on K562 transgenic cell lines harboring different copies of a lentiviral vector carrying the human β-globin gene, showing that γ-globin mRNA expression and HbF production can be induced in the presence of high levels of β-globin gene expression and HbA accumulation. We then treated erythroid progenitor cells from β-thalassemic patients with T9W, which expresses the human β-globin gene and mithramycin separately or in combination. When transduction with our lentiviral vector is insufficient to completely eliminate the unpaired α-globin chains, combination of β-globin gene transfer therapy together with fetal hemoglobin induction might be very efficacious to remove the excess of α-globin proteins in thalassemic erythroid progenitor cells. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
32. In VivoGene Transfer Strategies to Achieve Partial Correction of von Willebrand Disease.
- Author
-
Wang, Lan, Rosenberg, Jonathan B., De, Bishnu P., Ferris, Barbara, Wang, Rui, Rivella, Stefano, Kaminsky, Stephen M., and Crystal, Ronald G.
- Published
- 2012
- Full Text
- View/download PDF
33. Therapeutic Hemoglobin Levels after Gene Transfer in β-Thalassemia Mice and in Hematopoietic Cells of β-Thalassemia and Sickle Cells Disease Patients.
- Author
-
Breda, Laura, Casu, Carla, Gardenghi, Sara, Bianchi, Nicoletta, Cartegni, Luca, Narla, Mohandas, Yazdanbakhsh, Karina, Musso, Marco, Manwani, Deepa, Little, Jane, Gardner, Lawrence B., Kleinert, Dorothy A., Prus, Eugenia, Fibach, Eitan, Grady, Robert W., Giardina, Patricia J., Gambari, Roberto, and Rivella, Stefano
- Subjects
HEMOGLOBINS ,HEMOPROTEINS ,BLOOD pigments ,HEMOGLOBIN polymorphisms ,HEMOLYTIC anemia ,THALASSEMIA - Abstract
Preclinical and clinical studies demonstrate the feasibility of treating β-thalassemia and Sickle Cell Disease (SCD) by lentiviral-mediated transfer of the human β-globin gene. However, previous studies have not addressed whether the ability of lentiviral vectors to increase hemoglobin synthesis might vary in different patients. We generated lentiviral vectors carrying the human β-globin gene with and without an ankyrin insulator and compared their ability to induce hemoglobin synthesis in vitro and in thalassemic mice. We found that insertion of an ankyrin insulator leads to higher, potentially therapeutic levels of human β-globin through a novel mechanism that links the rate of transcription of the transgenic β-globin mRNA during erythroid differentiation with polysomal binding and efficient translation, as reported here for the first time. We also established a preclinical assay to test the ability of this novel vector to synthesize adult hemoglobin in erythroid precursors and in CD34
+ cells isolated from patients affected by β-thalassemia and SCD. Among the thalassemic patients, we identified a subset of specimens in which hemoglobin production can be achieved using fewer copies of the vector integrated than in others. In SCD specimens the treatment with AnkT9W ameliorates erythropoiesis by increasing adult hemoglobin (Hb A) and concurrently reducing the sickling tetramer (Hb S). Our results suggest two major findings. First, we discovered that for the purpose of expressing the β-globin gene the ankyrin element is particularly suitable. Second, our analysis of a large group of specimens from β-thalassemic and SCD patients indicates that clinical trials could benefit from a simple test to predict the relationship between the number of vector copies integrated and the total amount of hemoglobin produced in the erythroid cells of prospective patients. This approach would provide vital information to select the best candidates for these clinical trials, before patients undergo myeloablation and bone marrow transplant. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
34. A preclinical approach for gene therapy of β-thalassemia.
- Author
-
Breda, Laura, Kleinert, Dorothy A., Casu, Carla, Casula, Laura, Cartegni, Luca, Fibach, Eitan, Mancini, Irene, Giardina, Patricia J., Gambari, Roberto, and Rivella, Stefano
- Subjects
THALASSEMIA ,GENE therapy ,PHENOTYPES ,LENTIVIRUSES ,CLINICAL trials - Abstract
Lentiviral-mediated β-globin gene transfer successfully treated β-thalassemic mice. Based on this result, clinical trials were initiated. To date, however, no study has investigated the efficacy of gene therapy in relation to the nature of the different β-globin mutations found in patients. Most mutations can be classified as β
0 or β+ , based on the amount of β-globin protein produced. Therefore, we propose that a screening in vitro is necessary to verify the efficacy of gene transfer prior to treatment of individual patients. We used a two-phase liquid culture system to expand and differentiate erythroid progenitor cells (ErPCs) transduced with lentiviral vectors. We propose the use of this system to test the efficiency of lentiviral vectors carrying the human β-globin gene, to correct the phenotype of ErPCs from patients preparing for gene therapy. This new approach might have profound implications for designing gene therapy and for understanding the genotype/phenotype variability observed in Cooley's anemia patients. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
35. Hepcidin and Hfe in iron overload in β-thalassemia.
- Author
-
Gardenghi, Sara, Ramos, Pedro, Follenzi, Antonia, Rao, Niva, Rachmilewitz, Eliezer A., Giardina, Patricia J., Grady, Robert W., and Rivella, Stefano
- Subjects
IRON in the body ,THALASSEMIA ,HEMOGLOBINOPATHY ,MACROPHAGES ,IRON metabolism - Abstract
Hepcidin (HAMP) negatively regulates iron absorption, degrading the iron exporter ferroportin at the level of enterocytes and macrophages. We showed that mice with β-thalassemia intermedia ( th3/+) have increased anemia and iron overload. However, their hepcidin expression is relatively low compared to their iron burden. We also showed that the iron metabolism gene Hfe is down-regulated in concert with hepcidin in th3/+ mice. These observations suggest that low hepcidin levels are responsible for abnormal iron absorption in thalassemic mice and that down-regulation of Hfe might be involved in the pathway that controls hepcidin synthesis in β-thalassemia. Therefore, these studies suggest that increasing hepcidin and/or Hfe expression could be a strategy to reduces iron overload in these animals. The goal of this paper is to review recent findings that correlate hepcidin, Hfe, and iron metabolism in β-thalassemia and to discuss potential novel therapeutic approaches based on these recent discoveries. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
36. Iron metabolism and ineffective erythropoiesis in β-thalassemia mouse models.
- Author
-
Ramos, Pedro, Melchiori, Luca, Gardenghi, Sara, Van‐Roijen, Nico, Grady, Robert W., Ginzburg, Yelena, and Rivella, Stefano
- Subjects
THALASSEMIA ,ERYTHROPOIESIS ,GLOBIN genes ,IRON metabolism ,ANEMIA - Abstract
β-thalassemia is a disease associated with decreased β-globin production leading to anemia, ineffective erythropoiesis, and iron overload. New mechanisms associated with modulation of erythropoiesis and iron metabolism have recently been discovered in thalassemic mice, improving our understanding of the pathophysiology of this disease. These discoveries have the potential to be translated into clinically-relevant therapeutic options to reduce ineffective erythropoiesis and iron overload. A new generation of therapies based on limiting ineffective erythropoiesis, iron absorption, and the correction of iron maldistribution could be on the way, possibly complementing and improving the current standard of patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
37. Changes in bone microarchitecture and biomechanical properties in the th3 thalassemia mouse are associated with decreased bone turnover and occur during the period of bone accrual.
- Author
-
Vogiatzi, Maria G., Tsay, Jaime, Verdelis, Kostas, Rivella, Stefano, Grady, Robert W., Doty, Stephen, Giardina, Patricia J., and Boskey, Adele L.
- Subjects
OSTEOPOROSIS ,BONE fractures ,THALASSEMIA ,ANEMIA ,HEMOLYTIC anemia ,HEMOGLOBINS - Abstract
Osteoporosis and fractures occur frequently in patients with beta-thalassemias, a group of congenital hemolytic anemias characterized by decreased synthesis of the beta chain of hemoglobin. In this study, we determined the bone abnormalities of the th3 thalassemia mouse, generated by deletion of the mouse beta-chain genes. The heterozygous th3/+ mouse has moderate anemia and serves as a model of beta-thalassemia intermedia, which represents the mild thalassemia phenotype. The th3/th3 mouse has lethal anemia and is a model of beta-thalassemia major, which is characterized by life-threatening anemia requiring regular transfusions to sustain life. Compared to controls, (1) microCT of trabecular bone showed decreased bone volume fraction, number of trabeculae, and trabecular thickness in both th3/+ and th3/th3 (P < 0.05); (2) cortical bone analysis showed thinner cortices and increased marrow area in th3/+ (P < 0.05); (3) microCT abnormalities in th3/+ mice were present by 2 months and did not worsen with age; (4) histomorphometry was significant for decreased bone formation and resorption in both th3/+ and th3/th3, and expression of cathepsin K and osteocalcin from bone of both th3/+ and th3/th3 animals was reduced (P < 0.05); (5) biomechanics showed reduced maximum load, maximum moment, and structural stiffness in both th3/+ and th3/th3 (P < 0.01). In conclusion, the th3 mouse model of thalassemia manifests bone changes reminiscent of those in humans and can be used for further bone studies in thalassemia. Bone changes are associated with decreased bone turnover and develop early during the period of bone accrual. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
38. β-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload.
- Author
-
Melchiori, Luca, Gardenghi, Sara, and Rivella, Stefano
- Subjects
THALASSEMIA ,ERYTHROPOIESIS ,BLOOD transfusion ,ANEMIA ,HEMATOPOIESIS ,MONOGENIC & polygenic inheritance (Genetics) ,PATIENTS - Abstract
β-thalassemia encompasses a group of monogenic diseases that have in common defective synthesis of β-globin. The defects involved are extremely heterogeneous and give rise to a large phenotypic spectrum, with patients that are almost asymptomatic to cases in which regular blood transfusions are required to sustain life. As a result of the inefficient synthesis of β-globin, the patients suffer from chronic anemia due to a process called ineffective erythropoiesis (IE). The sequelae of IE lead to extramedullary hematopoiesis (EMH) with massive splenomegaly and dramatic iron overload, which in turn is responsible for many of the secondary pathologies observed in thalassemic patients. The processes are intimately linked such that an ideal therapeutic approach should address all of the complications. Although β-thalassemia is one of the first monogenic diseases to be described and represents a global health problem, only recently has the scientific community started to focus on the real molecular mechanisms that underlie this disease, opening new and exciting therapeutic perspectives for thalassemic patients worldwide. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
39. Production of β-globin and adult hemoglobin following G418 treatment of erythroid precursor cells from homozygous β039 thalassemia patients.
- Author
-
Salvatori, Francesca, Breveglieri, Giulia, Zuccato, Cristina, Finotti, Alessia, Bianchi, Nicoletta, Borgatti, Monica, Feriotto, Giordana, Destro, Federica, Canella, Alessandro, Brognara, Eleonora, Lampronti, Ilaria, Breda, Laura, Rivella, Stefano, and Gambari, Roberto
- Published
- 2009
- Full Text
- View/download PDF
40. Ineffective erythropoiesis and thalassemias.
- Author
-
Rivella S and Rivella, Stefano
- Published
- 2009
- Full Text
- View/download PDF
41. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera.
- Author
-
Weizer-Stern, Orly, Adamsky, Konstantin, Amariglio, Ninette, Levin, Carina, Koren, Ariel, Breuer, William, Rachmilewitz, Eliezer, Breda, Laura, Rivella, Stefano, Ioav Cabantchik, Z., and Rechavi, Gideon
- Subjects
THALASSEMIA ,ERYTHROPOIESIS ,LIVER ,IRON metabolism ,HEPATOCELLULAR carcinoma ,PATIENTS - Abstract
β-Thalassaemia represents a group of diseases, in which ineffective erythropoiesis is accompanied by iron overload. In a mouse model of β-thalassaemia, we observed that the liver expressed relatively low levels of hepcidin, which is a key factor in the regulation of iron absorption by the gut and of iron recycling by the reticuloendothelial system. It was hypothesised that, despite the overt iron overload, a putative plasma factor found in β-thalassaemia might suppress liver hepcidin expression. Sera from β-thalassaemia and haemochromatosis (C282Y mutation) patients were compared with those of healthy individuals regarding their capacity to induce changes the expression of key genes of iron metabolism in human HepG2 hepatoma cells. Sera from β-thalassaemia major patients induced a major decrease in hepcidin ( HAMP) and lipocalin2 (oncogene 24p3) ( LCN2) expression, as well as a moderate decrease in haemojuvelin ( HFE2) expression, compared with sera from healthy individuals. A significant correlation was found between the degree of downregulation of HAMP and HFE2 induced by β-thalassaemia major sera ( r = 0·852, P < 0·0009). Decreased HAMP expression was also found in HepG2 cells treated with sera from β-thalassaemia intermedia patients. In contrast, the majority of sera from hereditary haemochromatosis patients induced an increase in HAMP expression, which correlated with transferrin (Tf) saturation ( r = 0·765, P < 0·0099). Our results suggest that, in β-thalassaemia, serum factors might override the potential effect of iron overload on HAMP expression, thereby providing an explanation for the failure to arrest excessive intestinal iron absorption in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
42. Exploring the Role of Hepcidin, an Antimicrobial and Iron Regulatory Peptide, in Increased Iron Absorption in β-Thalassemia.
- Author
-
BREDA, LAURA, GARDENGHI, SARA, GUY, ELLA, RACHMILEWITZ, ELIEZER A., WEIZER‐STERN, ORLY, ADAMSKY, KONSTANTIN, AMARIGLIO, NINETTE, RECHAVI, GIDEON, GIARDINA, PATRICIA J., GRADY, ROBERT W., and RIVELLA, STEFANO
- Subjects
THALASSEMIA treatment ,ANTI-infective agents ,HEREDITY ,HEMOGLOBINOPATHY ,HEMOLYTIC anemia ,IRON in the body - Abstract
To develop new treatments for β-thalassemia, it is essential to identify the genes involved in the relevant pathophysiological processes. Iron metabolism in thalassemia mice being investigated, focusing on the expression of a gene called hepcidin (Hamp), which is expressed in the liver and whose product (Hamp) is secreted into the bloodstream. In mice, iron overload leads to overexpression of Hamp, while Hamp-knockout mice suffer from hemochromatosis. The aim of this study is to investigate Hamp in the mouse model of β-thalassemia and to address the potential gene transfer of Hamp to prevent abnormal iron absorption. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
43. Role of Iron in Inducing Oxidative Stress in Thalassemia: Can It Be Prevented by Inhibition of Absorption and by Antioxidants?
- Author
-
RACHMILEWITZ, ELIEZER A., WEIZER‐STERN, ORLY, ADAMSKY, KONSTANTIN, AMARIGLIO, NINETTE, RECHAVI, GIDEON, BREDA, LAURA, RIVELLA, STEFANO, and CABANTCHIK, Z IOAV
- Subjects
THALASSEMIA ,HEMOGLOBINOPATHY ,OXIDATIVE stress ,ANTIOXIDANTS ,ERYTHROCYTES ,RNA - Abstract
The pathophysiology of thalassemia is, to a certain extent, associated with the generation of labile iron in the pathological red blood cell (RBC). The appearance of such forms of iron at the inner and outer cell surfaces exposes the cell to conditions whereby the labile metal promotes the formation of reactive oxygen species (ROS) leading to cumulative cell damage. Another source of iron accumulation results from increased absorption due to decreased expression of hepcidin. The presence of labile plasma iron (LPI) was carried out using fluorescent probes in the FACS. RNA expression of hepcidin was measured in two models of thalassemic mice. Hepcidin expression was also measured in human hapatoma HepG2 cells following incubation with thalassemic sera. LPI was identified and could be quantitatively measured and correlated with other parameters of iron overload. Hepcidin expression was downregulated in the livers of thalassemic mice, in major more than in intermedia. Thalassemic sera down regulated hepcidin expression in HepG2 liver cells. A possible way to decrease iron absorption could be by modulating hepcidin expression pharmacologically, by gene therapy or by its administration. Treatment with combination of antioxidants such as N-acetylcysteine for proteins and vitamin E for lipids in addition to iron chelators could neutralize the deleterious effects of ROS and monitored by quantitation of LPI. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
44. Progress Toward the Genetic Treatment of the β- Thalassemias.
- Author
-
SADELAIN, MICHEL, LISOWSKI, LESZEK, SAMAKOGLU, SELDA, RIVELLA, STEFANO, MAY, CHAD, and RIVIERE, ISABELLE
- Subjects
THALASSEMIA ,GENE therapy ,GLOBIN genes ,HEMOLYTIC anemia ,HEMATOPOIETIC stem cell transplantation ,ANEMIA - Abstract
The β-thalassemias are congenital anemias that are caused by mutations that reduce or abolish expression of the β-globin gene. They can be cured by allogeneic hematopoietic stem cell (HSC) transplantation, but this therapeutic option is not available to most patients. The transfer of a regulated β-globin gene in autologous HSCs is a highly attractive alternative treatment. This strategy, which is simple in principle, raises major challenges in terms of controlling expression of the globin transgene, which ideally should be erythroid specific, differentiationand stage-restricted, elevated, position independent, and sustained over time. Using lentiviral vectors, May et al. demonstrated in 2000 that an optimized combination of proximal and distal transcriptional control elements permits lineage-specific and elevated β-globin expression, resulting in therapeutic hemoglobin production and correction of anemia in thalassemic mice. Several groups have by now replicated and extended these findings to various mouse models of severe hemoglobinopathies, thus fueling enthusiasm for a potential treatment of β-thalassemia based on globin gene transfer. Current investigation focuses on safety issues and the need for improved vector production methodologies. The safe implementation of stem cell-based gene therapy requires the prevention of the formation of replication competent viral genomes and minimization of the risk of insertional oncogenesis. Importantly, globin vectors, in which transcriptional activity is highly restricted, have a lesser risk of activating oncogenes in hematopoietic progenitors than non-tissue-specific vectors, by virtue of their late-stage erythroid specificity. As such, they provide a general paradigm for improving vector safety in stem cell-based gene therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
45. Globin gene transfer: a paradigm for transgene regulation and vector safety.
- Author
-
Rivella, Stefano, Lisowski, Leszek, and Sadelain, Michel
- Subjects
THALASSEMIA ,SICKLE cell anemia ,STEM cells ,GENE therapy ,MUTAGENESIS - Abstract
The β-thalassemias and sickle cell disease are severe congenital anemias that are caused by the defective synthesis of the β chain of hemoglobin. Allogeneic hematopoietic stem cell (HSC) transplantation is curative, but this therapeutic option is not available to the majority of patients. The transfer of a regulated β-globin gene in autologous HCSs thus represents a highly attractive alternative treatment. This strategy, simple in principle, raises major challenges in terms of controlling transgene expression, which ideally should be erythroid-specific, differentiation stage-restricted, elevated, position-independent, and sustained over time. Using lentiviral vectors, we recently demonstrated that an optimized combination of proximal and distal transcriptional control elements permits lineage-specific and elevated expression of the β-globin gene, resulting in therapeutic hemoglobin production and correction of anemia in β-thalassemic mice. Several groups have now confirmed and extended these findings in various mouse models of severe hemoglobinopathies, thus generating enthusiasm for a genetic treatment based on globin gene transfer. Furthermore, globin vectors provide a paradigm for improving vector safety by restricting transgene expression to the differentiated progeny within a single lineage, thereby reducing the risk of activating oncogenes in hematopoietic progenitors. Here we review the principles underlying the genesis of regulated vectors for stem cell therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
46. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.
- Author
-
May, Chad, Rivella, Stefano, Callegari, John, Heller, Glenn, Gaensler, Karen M.L., Luzzatto, Lucio, and Sadelain, Michel
- Subjects
HEMOGLOBIN synthesis ,LENTIVIRUSES ,THALASSEMIA ,SICKLE cell anemia - Abstract
Shows that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. Speculation that the stable introduction of a functional beta-globin gene in hemotopoietic stem cells could be a powerful approach to treat beta-thalassemia and sickle-cell disease; Findings of experiments with beta-thalassemic mice; Conclusion that such therapy should be of benefit to patients with severe defects in hemoglobin production.
- Published
- 2000
- Full Text
- View/download PDF
47. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy.
- Author
-
Bione, Silvia, Maestrini, Elena, Rivella, Stefano, Mancini, Mita, Regis, Stefano, Romeo, Giovanni, and Toniolo, Daniela
- Published
- 1994
- Full Text
- View/download PDF
48. Methylation and sequence analysis around Eagi sites: identification of 28 new CpG islands in XQ24-XQ28.
- Author
-
Tribioli, Carla, Tamanini, Filippo, Patrosso, Cristina, Milanesi, Luciano, Villa, Anna, Pergolizzi, Rossana, Maestrini, Elena, Rivella, Stefano, Bione, Silvia, Mancini, Mita, Vezzoni, Paolo, and Toniolo, Daniela
- Published
- 1992
49. CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of β-Thalassemia through an Increase in 20-HETE Activity.
- Author
-
Bou-Fakhredin, Rayan, Dia, Batoul, Ghadieh, Hilda E., Rivella, Stefano, Cappellini, Maria Domenica, Eid, Assaad A., Taher, Ali T., and Shimizu, Takahiko
- Subjects
REACTIVE oxygen species ,NICOTINAMIDE adenine dinucleotide phosphate ,CYTOCHROME oxidase ,LABORATORY mice ,CYTOCHROME P-450 - Abstract
Oxidative damage by reactive oxygen species (ROS) is one of the main contributors to cell injury and tissue damage in thalassemia patients. Recent studies suggest that ROS generation in non-transfusion-dependent (NTDT) patients occurs as a result of iron overload. Among the different sources of ROS, the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family of enzymes and cytochrome P450 (CYP450) have been proposed to be major contributors for oxidative stress in several diseases. However, the sources of ROS in patients with NTDT remain poorly understood. In this study, Hbb
th3/+ mice, a mouse model for β-thalassemia, were used. These mice exhibit an unchanged or decreased expression of the major NOX isoforms, NOX1, NOX2 and NOX4, when compared to their C57BL/6 control littermates. However, a significant increase in the protein synthesis of CYP4A and CYP4F was observed in the Hbbth3/+ mice when compared to the C57BL/6 control mice. These changes were paralleled by an increased production of 20-hydroxyeicosatetraenoic acid (20-HETE), a CYP4A and CYP4F metabolite. Furthermore, these changes corroborate with onset of ROS production concomitant with liver injury. To our knowledge, this is the first report indicating that CYP450 4A and 4F-induced 20-HETE production mediates reactive oxygen species overgeneration in Hbbth3/+ mice through an NADPH-dependent pathway. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
50. Analysis of alpha hemoglobin stabilizing protein overexpression in murine β-thalassemia.
- Author
-
Nasimuzzaman, Md, Khandros, Eugene, Wang, Xiaomei, Kong, Yi, Zhao, Huifen, Weiss, David, Rivella, Stefano, Weiss, Mitchell J., and Persons, Derek A.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.